3 assets in Hormone-Resistant Prostate Carcinoma

Therapeutic assets addressing Hormone-Resistant Prostate Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Enzalutamide Hormone-Resistant Prostate Carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P3	BB (68)
Pembrolizumab Hormone-Resistant Prostate Carcinoma	University of Wisconsin, Madison	P2	B (63)
Trametinib Hormone-Resistant Prostate Carcinoma	Jonsson Comprehensive Cancer Center	P2	CCC (53)